Innate Pharma and Novo Nordisk announce strategic partnership (in English)

The French biopharmaceutical company Innate Pharma SA and the Danish-based global healthcare company Novo Nordisk today announced a major partnership to develop new drugs targeting natural killer (NK) cells, one of the body’s first lines of defence against cancer and infections. As part of the agreement Novo Nordisk will invest 10 million EUR in new Innate Pharma equity.

Source: Press release from Novo Nordisk, 05.04.06.

Read more at Novo Nordisk homepage